Home | Introduction | Site Map | Success Stories | Research | Products | FAQ | Contact Us | WWC Audio |

 

 • Introduction
 •
Important Warning  
 •
About Vitamin B17
 •
Vitamin B17 as Preventative
 •
Metabolic Therapy in Cancer
 • B17 In Metabolic Therapy
 •
Laetrile and Cyanide
 •
Graphic on Action of B17
 •
Frequently Asked Questions
 •
B17 Therapy Components
 •
Accessory Supplements
 •
B17 Therapy Overview
 •
Therapies and Protocols
 •
What is in B17 Therapy?
 •
Maintenance Dosages
 •
Accessory Therapies
 •
Positive Thinking
 •
Implementing Changes
 •
Behaviour of Tumours
 •
Criteria For Evaluation
 •
B17 - Sickle Cell Anaemia
 •
Fluoridation-linked cancer
 •
Contacts 
 •
In God We Trust
 •
References

•  More Studies, Research

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

CHAPTER III

SOURCES AND METHODS FOR OBTAINING AMYGDALIN
Petra Beltran Corona
Chief of the Production Department of KEMSA LABS


 

The most currently utilized source for obtaining AMYGDALIN is the apricot pit, but it is also found in the seeds of fruits of the Rosaceas family, although in smaller proportion. The method for obtaining it has been standardized only after many years of research in several countries of Europe and America.

The pioneers in the obtaining of AMYGDALIN (from AMIGDALA=almond) were Robiquet and Boutron, who isolated it in pure form in 1830.

The key for obtaining high quality AMYGDALIN begins with an adequate selection of apricot pits and the careful process which is followed in the method for obtaining AMYGDALIN and includes the following steps:

Cleaning the Dry Nuts
The main purpose here is to eliminate the residue from the shell, peel, stones and leaves which could damage the mill and lower the yield from the process.

Milling the Nuts
Here most of the oil is separated in the first milling and the rest of it in subsequent millings. The final product of the milling is a fine, brown powder with a bitter smell which, upon letting it sit, ferments spontaneously, which is desirable inasmuch as it increases the yield.

Extraction of the Powder
This is done in a digester of stainless steel with isopropyl alcohol, at a constant temperature and reflux for two and one-half hours.

Filtering
The product from the extraction is passed through cloth filters with holes small enough to prevent passage of particles of the nut that have not been broken down. The filtered product is allowed to sit for 72 hours and separates into AMYGDALIN sediment and standing isopropyl alcohol which is completely eliminated after washing the AMYGDALIN several times with ethylic ether which is also a great, very volatile, grease solvent (which facilitates the elimination).

The product from this process is a dry, white powder.

Drying the Amygdalin
This is achieved after spreading out the AMYGDALIN in stainless steel trays which are placed in an oven for eight consecutive hours at temperatures from 500° to 600°C.

The product after drying can be identified by a degree of purity from 65 to 80 percent.

Crystallization
It is recommended that this be done in glass recipients with a closed top and smooth bottom. The AMYGDALIN is exposed to a mixture of activated carbon and inert ionized earth which acts as another filter. The product from this crystallization is refrigerated for four hours at 40°C. In order to increase the yield, the filtering, washing, drying and crystallization of the pulp that remains as a residue on the cloth filters can be repeated, although it is necessary to do a more intense washing with the ethylic ether and slight variations in the drying temperatures after crystallization.

The final product is AMYGDALIN with a purity of not less than 96%.

Principal Errors to Avoid
In order to avoid having the mixture tur rancid during the milling of the nuts, great care must be taken to clean the mills, assuring that no residual oil remains in them. During the drying, overheating must be avoided, because if it is prolonged, the quality of the AMYGDALIN will be lowered. Finally, special attention must be focused on the filtering process, since the better this is done, the greater the yield achieved.

The AMYGDALIN thus obtained has physical and chemical characteristics which allow it to be perfectly identified and differentiated in specific form, which facilitates its quantification and the control of its purity.

This AMYGDALIN can now undergo well-defined manufacturing steps which transform it into final products (tablets and vials) for oral use (KEMDALIN B) or parenteral (KEMDALIN S).

It should be mentioned that before going out onto the market, these end products routinely pass through the Quality Control Department for its analysis IN VITRO and in animals. These studies include routine tests for toxicity, fever causing impurities and sterility.

 

 

2001 Worldwithoutcancer.org.uk
By Accessing this web site you accept  all its terms and conditions.

©Copyright 2000 - Worldwithoutcancer.org.uk - PO Box 2038 - Leigh-on-Sea - SS9 2ZB - UK
Home | Introduction | Site Map | Success Stories | Research | Products | FAQ | Contact Us | WWC Audio |